|
BIOAF
|
I made a mistake. I thought that poof made the post about fighting for your...
|
|
BIOAF
|
I missed your final sentence, poof, "IF I can change ..... so can...
|
|
BIOAF
|
poof is wrong again! He says Monday is mid May. Nope. Noon on May 16th is...
|
|
BIOAF
|
Just a few small points. And some questions. Poof has been...
|
|
BIOAF
|
Zwerp says BTI didn't move on the FDA approval of PRX-102. Although that...
|
|
BIOAF
|
My understanding of xB3 drug development is that, as new chemical entities...
|
|
BIOAF
|
Protalix and Chiesi have announced that their enzyme replacement therapy for...
|
|
BIOAF
|
Yes, zwerp. Protalix, Chiesi, ProCellEx, Fabry disease and PRX-102 all could...
|
|
BIOAF
|
Here's a question for you, poof. Since Mark Day left Bioasis, has...
|
|
BIOAF
|
If Prothena's PRX012 is an xB3 drug, then because Alzheimer's is a...
|
|
BIOAF
|
It's true that Prothena's PRX012 could have been modified with xB3...
|
|
BIOAF
|
I know a hell of a lot more than what you might think I know, DM. ...
|
|
BIOAF
|
I know what Prothena's first target is/was and as you know, I can't...
|
|
BIOAF
|
I understand your argument, DM. Why was there never any penetration...
|
|
BIOAF
|
Best to be careful when considering any success Prothena might have with...
|
|
BIOAF
|
Let's be a little careful, DeadMonkey. J&J was around since RH's...
|
|
BIOAF
|
The Bioasis study with non-human primates back in 2018 DID NOT show that xB3...
|
|
BIOAF
|
Can you explain to us, poof, how RNAi might compete with the transport of...
|
|
BIOAF
|
Can you explain to us, poof, how RNAi might compete with the transport of...
|
|
BIOAF
|
We beat those monkey discussions to death years ago, gff. Cost, ethics and...
|